uploads/2017/07/Analysts-Recommendations-1.png

What Analysts Recommend for BioMarin Pharmaceuticals

By

Updated

Long-term growth drivers

In February 2017, the European Medical Agency (or EMA) through its Committee for Medicinal Products for Human Use (or CHMP) granted BioMarin Pharmaceuticals’ (BMRN) BMN 270 access to its Priority Medicines (or PRIME) regulatory initiative. BMN 270 is an investigational gene therapy indicated for severe hemophilia A therapy. The success in clinical trials and the approval of the drug by regulatory bodies around the world will help BMRN commercialize the gene therapy for hemophilia A worldwide.

Article continues below advertisement

In June 2017, BioMarin Pharmaceuticals submitted a biologics license application (or BLA) to the Food and Drug Administration (or FDA) for Pegvaliase to be indicated for the treatment of patients with phenylketonuria. Pegvaliase is a recombinant phenylalanine ammonia lyase enzyme based on the principle of enzyme replacement therapy. The approval of the drug will add a drug to BMRN’s product portfolio, which is expected to push revenue growth for the long term. The iShares Russell Mid-Cap Growth ETF (IWP) invests ~0.57% of its total portfolio holdings in BioMarin Pharmaceuticals.

Analyst recommendations

A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.” Five analysts suggested a “hold,” while none of the analysts recommended a “sell” or “strong sell.” Around 75% of the analysts recommended some form of buy.

Article continues below advertisement

Competitors’ ratings

Of the 20 analysts analyzing Alexion Pharmaceuticals (ALXN) in July 2017, five recommended a “strong buy,” while 11 analysts recommended a “buy.” Four analysts recommended a “hold,” and none of the analysts recommended a “sell” or “strong sell.” ~80% of the analysts analyzing Alexion Pharmaceuticals suggested some form of buy.

Out of 25 analysts analyzing Amgen (AMGN) in July 2017, three analysts recommended a “strong buy,” while eight analysts recommended a “buy.” 14 analysts recommended a “hold,” ~48% of analysts recommended some form of “buy,” and none suggested a “sell.”

Of the ten analysts analyzing Ionis Pharmaceuticals (IONS) in July 2017, one analyst recommended a “strong buy,” while three analysts suggested a “buy.” Five analysts suggested a hold while one analyst suggested a “strong sell.” Around 40% of the analysts analyzing Ionis Pharmaceuticals supported some form of buy.

Advertisement

More From Market Realist